Thank you for your comments.
My post is in no way meant to downgrade the achievements of the IMU Board, nor the stock price. Since embarking on the IMU journey we have more than doubled our capital base and are staring down the barrel of a much broader pipeline with immeasurable opportunities in the OV, Oncarlytics, HER 2 and PD1 - PD-L1 space. We have consistently purchased shares, from 2 cents to 60 cents, and all the way back down again. I am in no way advocating a 100% share sale, takeover or B cell sale, as suggested by some. I merely see Imugene at an inflection point, from which they can potentially grow immeasurably, in the event of a sound commercial strategy, or continue on their R&D "follow the science" path by adding value to their existing pipeline. For me striking a commercial deal now with a Big Pharma i.e., Pfizer, who seeks to become a leading player in the cancer treatment space, would be advantageous. Such a partnership would enable Imugene to broaden their existing pipeline, fast track existing drugs from trial to production, and fully develop their attack on the solid tumour market.
The fact remains, IMU is not in a financial position to manufacture, market and sell their drugs post production. They just don't have the funds. Therefore they require at some stage, to either raise more capital, sell their drugs to a larger player or partner with a healthcare company to manufacture and sell their drugs. Are their existing drugs going to be more valuable in one years time? Yes. But what if they had the capital to trial three times as many drugs and combination therapies? What if they had teams of professionals working with the FDA to seek approvals for TIGS, OV's, Oncarlytics programs and PD1-PD-L1 combinations. Remember IMU is not the only gun in town. There are a myriad of companies, research houses and scientists shooting for the title "cure for cancer". There are already HER 2, PD1-PD-L1, OV and Oncarlytics providers honing their dosage rates and strengthening their existing sales. There are a multitude of biotech companies seeking FDA approval for their suite of cancer drugs. Speed to market is important, particularly when one considers many existing cancer treatments therapies are already becoming obsolete in the wake of new cancer remedies. A partnership based upon milestone payments could enhance Imugene's current position through access to additional capital, a greater pool of Human Resources, knowledge and marketing expertise. The company could potentially reach economies of scale much sooner than they would otherwise. And one would envisage they would ultimately be the beneficiary of reduced manufacturing costs, lower borrowing margins, infinite combination opportunities and the potential to export into their partners already existent sales base.
Some posters are eluding to the fact I am listening to and buckling under the pressure of many individuals on these HC threads. To the contrary these are my own opinions and they are not influenced in any way by background noise or a need to acquiesce with anyone. I merely see now as being the opportune time from a financial, monetary and market perspective for Imugene to clearly outline a path forward other than proceeding with existing trials and developing their pipeline. Are they going to be successful if they continue on their existing path? Undoubtedly yes. Could they be ultimately more successful if they strategically position themselves for long term growth without the need to sell drugs as and when they reach Phase 3? I think so. Without the need to raise more capital? I think so. Without the need to rely on the small ASX market with its ebb's and flows and underlying reliance on the minerals market for strength? I think so.
Please do not misconstrue my sentiments. I am very happy and comfortable with our long term investment in Imugene. It is without doubt the best investment decision we have made, and the future is looking brighter by the day, under the hardworking ethical leadership of Imugene's CEO Lesley Chong. This outlook need not change, it may well be enhanced, through the inception of a sound, mutually beneficial commercial agreement between Imugene and a Big Pharma partner.
Best of luck to all LTH's. Great buying opportunities exist in IMU for those with funds on hand now.
DYOR - Seek investment advice where applicable - these are my opinions only
Expand
(20min delay)
